Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mannatech Reports Results From Ambrotose Study
The company said that Talitha Best and Eva Kemps of Flinders University in Adelaide and Janet Bryan of the University of South Australia in Adelaide, have published their
The company said that Talitha Best and Eva Kemps of Flinders University in Adelaide and Janet Bryan of the University of South Australia in Adelaide, have published their
Novo Nordisk and the Swedish university consortium, ‘Combine’ have formed a research collaboration in the field of autoimmune diseases. Under the agreement, Novo Nordisk will work with scientists
Teva has entered into two agreements with AstraZeneca to settle patent litigation regarding Teva’s US generic versions of AstraZeneca’s Prilosec (omeprazole) and Nexium (esomeprazole), including all claims for
Ceragenix has entered into an exclusive distribution and supply agreement with BioPro Pharmaceutical, to commercialize EpiCeram, a prescription topical cream for treating atopic dermatitis and other dry skin
Vical has announced that systematic in vivo testing of its Vaxfectin adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the immune system rather than
Vivus has reported positive results from a phase 2 study evaluating the safety and efficacy of Qnexa, an investigational drug, for the treatment of obstructive sleep apnea (OSA).
Elixir Pharmaceuticals has reported that its partner, Siena Biotech has commenced phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of huntington’s disease.
Ardea Biosciences (Ardea) has reported additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
Laureate Pharma (Laureate) and Iconic Therapeutics (Iconic) have completed the manufacturing of the first GMP lot of hI-con1, a recombinant Fc-Factor VII fusion protein. hI-con1 is a recombinant
Sciele Pharma has introduced Adrenaclick, a single-dose, epinephrine auto-injector, for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis. Adrenaclick is expected to be available